Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Non Operating Income (2016 - 2026)

Ocular Therapeutix has reported Non Operating Income over the past 14 years, most recently at $4.7 million for Q1 2026.

  • For Q1 2026, Non Operating Income rose 3576.47% year-over-year to $4.7 million; the TTM value through Mar 2026 reached $8.9 million, down 21.36%, while the annual FY2025 figure was $4.1 million, 118.77% up from the prior year.
  • Non Operating Income for Q1 2026 was $4.7 million at Ocular Therapeutix, down from $5.1 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $18.7 million in Q3 2023 and troughed at -$33.2 million in Q1 2024.
  • A 5-year average of $241823.5 and a median of -$1000.0 in 2023 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 114900.0% in 2022 and later crashed 3323000.0% in 2024.
  • Year by year, Non Operating Income stood at $3.8 million in 2022, then tumbled by 340.12% to -$9.2 million in 2023, then surged by 123.86% to $2.2 million in 2024, then soared by 133.36% to $5.1 million in 2025, then decreased by 7.4% to $4.7 million in 2026.
  • Business Quant data shows Non Operating Income for OCUL at $4.7 million in Q1 2026, $5.1 million in Q4 2025, and -$720000.0 in Q3 2025.